Thiobarbituric

Thiobarbituric

SCHEMBL2344775

O=C1CC(=O)NC(=S)N1.[Na]

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
CRBN Q96SW2 2/20 0.35
MAPT P10636 1/20 0.34
ITGB3 P05106 1/20 0.33
ITGB1 P05556 1/20 0.33
ITGAV P06756 1/20 0.33
ITGA4 P13612 1/20 0.33
ALDH1A1 P00352 3/20 0.32
AHR P35869 1/20 0.32
PDK2 Q15119 1/20 0.32
CYP1A2 P05177 1/20 0.32
HPGD P15428 1/20 0.32
HIF1A Q16665 1/20 0.32
HSD17B10 Q99714 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
POLB P06746 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Thiobarbituric SCHEMBL31059040 0.97 GSK3A (0.38) GSK3AGSK3BCRBNMAPTITGB3
Thiobarbituric SCHEMBL16027 0.97
Thiobarbituric SCHEMBL2351184 0.94 GSK3A (0.36) GSK3AGSK3BCRBNMAPTITGB3
Thiobarbituric SCHEMBL8216351 0.94 GSK3A (0.36) GSK3AGSK3BCRBNMAPTITGB3
Barbituric Acid SCHEMBL4726594 0.88 ALDH1A1 (0.44) GSK3AGSK3BCRBNMAPTITGB3
Thiobarbituric SCHEMBL144675 0.84 ITGB3 (0.33) GSK3AGSK3BMAPTITGB3ITGB1
Thiobarbituric SCHEMBL7714190 0.84 ALDH1A1 (0.42) GSK3AGSK3BMAPTALDH1A1CYP1A2
SCHEMBL8028070 0.82
Thiobarbituric SCHEMBL2455746 0.82 ITGB3 (0.32) GSK3AGSK3BITGB3ITGB1ITGAV
Thiobarbituric SCHEMBL1867943 0.80 ALDH1A1 (0.33) GSK3AGSK3BITGB3ITGB1ITGAV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115572597-B Thiobarbituric acid-gold nanocluster and preparation method and application thereof 青岛大学 2024-09-10 CN claimed
CN-115572597-A Thiobabituric acid-gold nanocluster and preparation method and application thereof 青岛大学 2023-01-06 CN claimed
US-8859769-B2 Processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine ACTAVIS GROUP PTC EHF (IS) 2014-10-14 US claimed
US-20130030176-A1 PROCESSES FOR PREPARING TICAGRELOR INTERMEDIATE, 4,6-DICHLORO-5-NITRO-2-(PROPYLTHIO)PYRIMIDINE ACTAVIS GROUP PTC EHF (IS) 2013-01-31 US claimed
EP-2536695-A1 IMPROVED PROCESSES FOR PREPARING TICAGRELOR INTERMEDIATE, 4,6-DICHLORO-5-NITRO-2-(PROPYLTHIO)PYRIMIDINE Actavis Group Ptc Ehf (IS) 2012-12-26 EP claimed
WO-2011101740-A1 IMPROVED PROCESSES FOR PREPARING TICAGRELOR INTERMEDIATE, 4,6-DICHLORO-5-NITRO-2-(PROPYLTHIO)PYRIMIDINE ACTAVIS GROUP PTC EHF (IS) 2011-08-25 WO claimed
CN-121714568-A Sophocarpine and application thereof in inhibiting formation of subretinal fibrosis 上海优祺生物医药科技有限公司 2026-03-24 CN disclosed
CN-119948115-A Azo dye, dye composition, colorant for anodic aluminum oxide, coloring method, and method for producing the dye 保土谷化学工业株式会社 2025-05-06 CN disclosed
CN-115572597-B Thiobarbituric acid-gold nanocluster and preparation method and application thereof 青岛大学 2024-09-10 CN disclosed
WO-2024070669-A1 AZO PIGMENT, DYE COMPOSITION, COLORANT AND COLORING METHOD FOR POSITIVE ELECTRODE ALUMINUM OXIDE, AND METHOD FOR PRODUCING AZO PIGMENT 保土谷化学工業株式会社 2024-04-04 WO disclosed
CN-115572597-A Thiobabituric acid-gold nanocluster and preparation method and application thereof 青岛大学 2023-01-06 CN disclosed
US-8859769-B2 Processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine ACTAVIS GROUP PTC EHF (IS) 2014-10-14 US disclosed
US-20130317220-A1 NOVEL PROCESSES FOR PREPARING TRIAZOLO[4, 5-d]PYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF ACTAVIS GROUP PTC EHF (IS) 2013-11-28 US disclosed
US-20130030176-A1 PROCESSES FOR PREPARING TICAGRELOR INTERMEDIATE, 4,6-DICHLORO-5-NITRO-2-(PROPYLTHIO)PYRIMIDINE ACTAVIS GROUP PTC EHF (IS) 2013-01-31 US disclosed
EP-2536695-A1 IMPROVED PROCESSES FOR PREPARING TICAGRELOR INTERMEDIATE, 4,6-DICHLORO-5-NITRO-2-(PROPYLTHIO)PYRIMIDINE Actavis Group Ptc Ehf (IS) 2012-12-26 EP disclosed
WO-2012085665-A2 NOVEL PROCESSES FOR PREPARING TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF ACTAVIS GROUP PATC EHF (IS) 2012-06-28 WO disclosed
WO-2011101740-A1 IMPROVED PROCESSES FOR PREPARING TICAGRELOR INTERMEDIATE, 4,6-DICHLORO-5-NITRO-2-(PROPYLTHIO)PYRIMIDINE ACTAVIS GROUP PTC EHF (IS) 2011-08-25 WO disclosed
US-4942155-A ANTIBIOTICS AND ANTITUMOR AGENTS FARMITALIA CARLO ERBA S.P.A. (IT) 1990-07-17 US disclosed
EP-0239774-B1 NEW BIOSYNTHETIC ANTHRACYCLINES RELATED TO DAUNORUBICIN FARMITALIA CARLO ERBA S.r.l. (IT) 1989-06-21 EP disclosed
EP-0239774-A1 New biosynthetic anthracyclines related to daunorubicin FARMITALIA CARLO ERBA S.r.l. (IT) 1987-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130317220-A1 NOVEL PROCESSES FOR PREPARING TRIAZOLO[4, 5-d]PYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF TBXAS1, TBXA2R, THPO GSK3A 3217/4885GSK3B 3428/4885CRBN 3406/4885
US-20130030176-A1 PROCESSES FOR PREPARING TICAGRELOR INTERMEDIATE, 4,6-DICHLORO-5-NITRO-2-(PROPYLTHIO)PYRIMIDINE THPO, NUDT1, DPYD GSK3A 4526/4885GSK3B 4500/4885CRBN 3433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.